Actinium Pharmaceuticals, Inc. (ATNM)
D
Pipeline Grade
Financial Position (from SEC Filings)
$42.5M
Cash & Equivalents
$5.9M
Quarterly Burn Rate
22 mo
Est. Cash Runway
$29M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase1 Readout | — |
| 2026-12-31 | Phase2 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07150806 | RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma | PHASE2 | Recruiting | 30 |
| NCT06726161 | Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Gl... | PHASE2 | Recruiting | 590 |
| NCT06590857 | Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing... | PHASE2 | Active Not Recruiting | 16 |
| NCT06736418 | Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Pla... | PHASE1 | Active Not Recruiting | 17 |
| NCT07156565 | Actinium Therapy for Late-stage Aggressive Sarcomas | PHASE1 | Recruiting | 30 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.